No connection

Search Results

PRTA

BEARISH
$10.9 Live
Prothena Corporation plc · NASDAQ
Target $21.0 (+92.7%)
$4.32 52W Range $11.69
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026
Market cap
$586.78M
P/E
N/A
ROE
-63.6%
Profit margin
N/A
Debt/Equity
0.03
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
PRTA exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor operational health. While the company maintains a strong liquidity position with a Current Ratio of 7.72 and minimal debt, its operational metrics are catastrophic, featuring a -99% YoY revenue collapse and an extreme negative operating margin. The stock is currently a speculative biotech play where valuation is decoupled from fundamentals, as evidenced by a Price/Sales ratio of 60.59. Despite a bullish analyst target of $21.00, the deterministic data suggests a high-risk profile with no current path to profitability.

Key Strengths

Very high liquidity (Current Ratio 7.72)
Negligible debt levels (Debt/Equity 0.03)
Strong short-term price momentum (+26.9% in 1 month)
Significant gap between current price and analyst target price ($21.00)
Low bankruptcy risk in the immediate term due to cash reserves

Key Risks

Near-total collapse of revenue (-99% YoY)
Extreme operational inefficiency (Operating Margin -129,576%)
Critical failure in financial health metrics (Piotroski 1/9)
Negative long-term price trajectory (-54.1% over 5 years)
Complete lack of earnings and dividend profile

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
20
Weak
Value
10
Future
30
Past
20
Health
40
Dividend
0
AI Verdict
Speculative/High Risk
Key drivers: Piotroski F-Score 1/9, Revenue Growth -99%, High Liquidity, Extreme P/S Ratio
Confidence
90%
Value
10/100

Ref P/E N/A, P/S 60.59, Graham Number None

Positives
  • Price/Book is relatively moderate at 2.09
Watchpoints
  • Price/Sales of 60.59 is unsustainable
  • No Graham Number available due to lack of earnings
Future
30/100

Ref Revenue Growth -99.00%

Positives
  • Analyst target price suggests 92% upside
Watchpoints
  • Revenue growth is effectively zero or negative
  • Consistent quarterly losses
Past
20/100

Ref 5Y Change -54.1%

Positives
  • Recent 1-year recovery (+18.5%)
Watchpoints
  • Severe 3-year and 5-year decline
  • History of missing earnings estimates
Health
40/100

Ref Piotroski F-Score 1/9, Current Ratio 7.72

Positives
  • Excellent Current and Quick ratios
  • Very low Debt/Equity
Watchpoints
  • Piotroski F-Score of 1/9 is a major red flag for operational viability
Dividend
0/100

Ref Dividend Yield N/A

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • No payout capacity

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$10.9
Analyst Target
$21.0
Upside/Downside
+92.7%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PRTA and closest competitors.

Updated 2026-04-17
PRT
Prothena Corporation plc
Primary
5Y
-54.1%
3Y
-79.5%
1Y
+18.5%
6M
+9.9%
1M
+26.9%
1W
+3.8%
HST
HealthStream, Inc.
Peer
5Y
-8.4%
3Y
-25.8%
1Y
-36.2%
6M
-22.1%
1M
-3.1%
1W
-2.8%
MDX
MiMedx Group, Inc.
Peer
5Y
-67.5%
3Y
+18.4%
1Y
-42.1%
6M
-39.8%
1M
-10.5%
1W
+1.0%
IRW
Ironwood Pharmaceuticals, Inc.
Peer
5Y
-64.3%
3Y
-66.3%
1Y
+259.4%
6M
+128.3%
1M
-1.4%
1W
+2.5%
LYE
Lyell Immunopharma, Inc.
Peer
5Y
-92.7%
3Y
-47.5%
1Y
+178.7%
6M
+47.4%
1M
+16.7%
1W
+14.3%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-10.48
PEG Ratio
N/A
P/B Ratio
2.09
P/S Ratio
60.59
EV/Revenue
29.7
EV/EBITDA
-1.57
Market Cap
$586.78M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -129576.0%
Gross Margin N/A
ROE -63.62%
ROA -26.4%

Growth

Revenue and earnings growth rates

Revenue Growth -99.0%
Earnings Growth N/A
Q/Q Revenue Growth -99.01%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.03
Low debt
Current Ratio
7.72
Strong
Quick Ratio
7.53
Excellent
Cash/Share
$5.71

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Op. Margin
-129576.2%
Net Margin
-102804.8%
Total Assets
$0.3B
Liabilities
$0.0B
Equity
$0.3B
Debt/Equity
0.17x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-02-19
$-0.46
+0.7% surprise
2025-11-06
$-0.67
-24.6% surprise
2025-08-04
$-1.73
+3.3% surprise

Healthcare Sector Comparison

Comparing PRTA against 418 companies in the Healthcare sector (24 bullish, 134 neutral, 260 bearish)
Return on Equity (ROE)
-63.62%
This Stock
vs
-101.05%
Sector Avg
-37.0% (Below Avg)
Debt to Equity
0.03
This Stock
vs
3.24
Sector Avg
-99.1% (Less Debt)
Revenue Growth
-99.0%
This Stock
vs
121.5%
Sector Avg
-181.5% (Slower)
Current Ratio
7.72
This Stock
vs
4.55
Sector Avg
+69.5% (Stronger)

Similar Companies

Peer comparison within the same industry

PRTA Prothena Corporation plc
BEARISH
Mkt Cap
$587M
P/E
-
ROE
-63.6%
Price
$10.9
HSTM HealthStream, Inc.
BEARISH
Mkt Cap
$590M
P/E
32.6
ROE
5.1%
Price
$19.88
 Compare with PRTA
MDXG MiMedx Group, Inc.
NEUTRAL
Mkt Cap
$582M
P/E
12.2
ROE
21.6%
Price
$3.92
 Compare with PRTA
IRWD Ironwood...
BEARISH
Mkt Cap
$592M
P/E
24.2
ROE
-%
Price
$3.63
 Compare with PRTA
LYEL Lyell...
BEARISH
Mkt Cap
$579M
P/E
-
ROE
-87.0%
Price
$24.8
 Compare with PRTA

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-03-27

PRTA filed a definitive proxy statement on March 27, 2026, providing shareholders with necessary information and materials for an upcoming vote.

8-K
8-K
2026-02-27

PRTA filed an 8-K on February 27, 2026, likely to announce its fiscal year-end financial results.

10-K
10-K
2026-02-27

PRTA filed its annual 10-K on February 27, 2026, providing disclosures regarding its business operations, risk factors, and financial condition. Specific financial highlights and risk details were not provided in the available excerpts.

8-K
8-K
2026-02-19

PRTA filed an 8-K on February 19, 2026, likely to announce its annual financial results for the preceding fiscal year.

8-K
8-K
2025-12-12
8-K
8-K
2025-11-19
10-Q
10-Q
2025-11-06

PRTA filed its quarterly 10-Q report on November 6, 2025. The filing includes a section on Risk Factors under Item 1A, although specific financial highlights and detailed risk descriptions were not provided in the available excerpt.

8-K
8-K
2025-11-06

PRTA filed an 8-K on November 6, 2025, likely to announce its third-quarter financial results.

DEF 14A
DEF 14A
2025-10-07

PRTA filed a definitive proxy statement (DEF 14A) on October 7, 2025, providing shareholders with information required to vote on matters at an upcoming meeting.

8-K
8-K
2025-08-27
8-K
8-K
2025-08-06
10-Q
10-Q
2025-08-04
8-K
8-K
2025-08-04
8-K
8-K
2025-07-30
8-K
8-K
2025-06-18
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
NONE
5 analysts
RBC Capital
2026-02-20
Maintains
Sector Perform Sector Perform
Citizens
2025-12-01
Maintains
Market Outperform Market Outperform
HC Wainwright & Co.
2025-11-07
Maintains
Buy Buy
RBC Capital
2025-11-07
Maintains
Sector Perform Sector Perform
Piper Sandler
2025-10-28
Maintains
Overweight Overweight

Past News Coverage

Recent headlines mentioning PRTA from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile